Thursday, October 29, 2026
12:00 pm - 1:00 pm CT/1:00 - 2:00 pm ET
Register
Description:
Join us for Part 3 of our Diagnostic Stewardship webinar series on Blood Stream Infections!
Bloodstream infections are a frequent cause of hospital morbidity and mortality. However, navigating positive blood cultures can be a challenge. Some organisms are contaminants, and overtreatment of a positive culture can lead to adverse effects. On the other hand, some organisms are almost always considered pathogens and there are differences in recommendations related to repeat blood cultures based on the specific pathogen that is isolated.
This interprofessional education session will enhance participants’ understanding of the clinical utility and limitations of diagnostic tools for bloodstream infections, emphasizing evidence-based practices that balance diagnostic value, patient safety, and antimicrobial stewardship principles. Through improved alignment of diagnostic decisions across the healthcare team, participants will strengthen collaboration and optimize patient outcomes.
Agenda:
Following introductions, speakers will use of diagnostic testing for blood stream infections with a focus on diagnostic stewardship. The session will end with attendee Q&A.
Target Audience: An interprofessional audience, specifically pharmacists and physicians, involved in the diagnosis and management of infectious diseases. The content may also apply to advanced practice providers, nurses, microbiologists, infection preventionists, and other healthcare professionals.
Learning Objectives:
- Describe current blood culture diagnostic stewardship evidence
- Apply rapid diagnostics, repeat blood culturing guidance, and antibiotic stewardship principles
- Review evidence supporting clinical decision support tools
- Compare and contrast successes and challenges of implementation
Faculty:
Kimberly C. Claeys, PharmD, PhD
Associate Professor
University of Maryland School of Pharmacy
Baltimore, MD
KC Coffey, MD, MPH
Medical Director Infection Control
Physician, Division of Infectious Diseases
Massachusetts General Hospital
Accreditation:
Pharmacist
The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0672-0000-26-051-L01-P
CPE credit: 1.0 contact hour (0.1 CEU)
Type of activity: Application
Release date: October 29, 2026
ACPE Activity Fee: SIDP Member: Free / Non-Member: $10
To receive CE credit, participants must view the CE content, complete a post-test, and complete an evaluation. Proof of completion will be submitted to NABP CPE Monitor.
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Participants are responsible for verifying credits were transferred successfully to your NABP eProfile account before the ACPE 60-day deadline. After the 60 day deadline, SIDP will no longer be able to report your credit(s) for this activity.
Funding: This activity is provided by SIDP. No external funding was received for this activity.
Disclosures: In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, SIDP asks all individuals involved in the development and presentation of CE activities to disclose all financial relationships with ineligible companies. All relevant financial relationships have been mitigated prior to the CE activity. The following financial relationships have been disclosed:
- Dr. Claeys - advisory board for GSK, external grants from Qlinea Diagnostics, Institution for Healthcare Improvement, Patient Centered Clinical Outcomes Research Institute
- Dr. Coffey - receives royalties from UpToDate, serves on editorial board for Journal Clinical Microbiology, contracts with CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator)
- Planning committee - Bryan White – consultant/advisor/speaker for Melinta, Mark Biagi – stock ownership Akero therapeutics, Anixa Biosciences, BriaCell Therapeutics, Cabaletta Bio, CRISPR Therapeutics, ProQR Therapeutics, ProQR Therapeutics, Recursion Pharmaceuticals, Summit Therapeutics, Syndax Pharmaceuticals, Vertex Pharmaceuticals, Viking Therapeutics, Maureen Campion – research funding from Paratek.
- Presentation title and objectives were written by the planning committee and enhanced by AI. All enhancements were reviewed by a human.
Disclaimer: Faculty members are asked to disclose when any unlabeled/investigational use of pharmaceuticals and devices is being discussed. This activity is intended for educational purposes and should not be used as a substitute for care or advice from a professional. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of SIDP.
The planners and faculty of this continuing education activity have made all reasonable efforts to ensure the accuracy of the information presented in accordance with the latest available scientific knowledge at the time of publication. Healthcare professionals should verify all information and data with recommendations of other authorities before treating patients or employing any therapies described in this continuing education activity.
.gif){kind=logo}